These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9186171)

  • 41. Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs?
    Weissgarten J; Zaidenstein R; Fishman S; Dishi V; Michovitz-Koren M; Averbukh Z; Golik A
    Perit Dial Int; 1999; 19(2):180-2. PubMed ID: 10357195
    [No Abstract]   [Full Text] [Related]  

  • 42. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A case of convulsion, loss of consciousness and subsequent acute renal failure caused by enoxacin and fenbufen].
    Morita H; Maemura K; Sakai Y; Kaneda Y
    Nihon Naika Gakkai Zasshi; 1988 May; 77(5):744-5. PubMed ID: 3216153
    [No Abstract]   [Full Text] [Related]  

  • 44. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO; Hjelm CJ; Canepo-Anson R
    Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract]   [Full Text] [Related]  

  • 45. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

  • 46. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate.
    Beghin L; Capps N; Duhal N; Davies J; Staels B; Luc G
    Ann Clin Biochem; 1999 Jul; 36 ( Pt 4)():523-5. PubMed ID: 10456219
    [No Abstract]   [Full Text] [Related]  

  • 47. CORONARY EFFECT OF FIBRATES ON PROTEINS AND ENZYMES WHICH HYDROLYZE TRIACYLGLYCEROLS.
    Francik R; Kryczyk J; Francik S
    Acta Pol Pharm; 2016; 73(3):579-88. PubMed ID: 27476274
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
    Maiguma T; Fujisaki K; Itoh Y; Makino K; Teshima D; Takahashi-Yanaga F; Sasaguri T; Oishi R
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):289-96. PubMed ID: 12644902
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
    Broeders N; Knoop C; Antoine M; Tielemans C; Abramowicz D
    Nephrol Dial Transplant; 2000 Dec; 15(12):1993-9. PubMed ID: 11096145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rhabdomyolysis with simvastatin and nefazodone.
    Thompson M; Samuels S
    Am J Psychiatry; 2002 Sep; 159(9):1607. PubMed ID: 12202291
    [No Abstract]   [Full Text] [Related]  

  • 52. Acute renal failure after cardiopulmonary bypass: a possible association with drugs of the fibrate group.
    Sharobeem KM; Madden BP; Millner R; Rolfe LM; Seymour CA; Parker J
    J Cardiovasc Pharmacol Ther; 2000 Jan; 5(1):33-9. PubMed ID: 10687672
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Fibrate-induced increase in serum creatinine levels: two cases].
    Décaudin B; Beraud G; Lannoy D; Semjen E; Wierre L; Horrent S; Résibois JP; Azar R; Odou P
    Therapie; 2005; 60(6):601-2. PubMed ID: 16555504
    [No Abstract]   [Full Text] [Related]  

  • 54. [Drug-induced rhabdomyolysis].
    Ueda S
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():567-71. PubMed ID: 18072348
    [No Abstract]   [Full Text] [Related]  

  • 55. Life-threatening hyperkalemia after 2 days of ibuprofen.
    Platts-Mills TF; Richmond NL; Hunold KM; Bowling CB
    Am J Emerg Med; 2013 Feb; 31(2):465.e1-2. PubMed ID: 23407039
    [No Abstract]   [Full Text] [Related]  

  • 56. [The treatment of chronic ischemic heart disease: the potentials for hypolipidemic correction using current drugs].
    Tashchuk VK; Makoviĭchuk IO; Bilets'kyĭ SV; Hrechko SI; Polishchuk OIu; Turubarova NA
    Lik Sprava; 1998; (5):101-3. PubMed ID: 9793321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure.
    Akoglu H; Yilmaz R; Kirkpantur A; Arici M; Altun B; Turgan C
    Ann Pharmacother; 2007 Jan; 41(1):143-7. PubMed ID: 17148651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simvastatin, fenofibrate, and rhabdomyolysis.
    Jacob SS; Jacob S; Williams C; Deeg MA
    Diabetes Care; 2005 May; 28(5):1258. PubMed ID: 15855605
    [No Abstract]   [Full Text] [Related]  

  • 59. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
    Lupp A; Karge E; Deufel T; Oelschlägers H; Fleck C
    Arzneimittelforschung; 2008; 58(5):225-41. PubMed ID: 18589557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E; Kostoula A; Elisaf M; Mikhailidis DP
    Angiology; 2002; 53(3):273-7. PubMed ID: 12025914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.